| Literature DB >> 29739336 |
Shobana Sekar1,2,3, Lori Cuyugan1,2, Jonathan Adkins1,2, Philipp Geiger1,2, Winnie S Liang4,5,6.
Abstract
BACKGROUND: Circular RNAs (circRNAs) are a novel class of endogenous, non-coding RNAs that form covalently closed continuous loops and that are both highly conserved and abundant in the mammalian brain. A role for circRNAs in sponging microRNAs (miRNAs) has been proposed, but the circRNA-miRNA-mRNA interaction networks in human brain cells have not been defined. Therefore, we identified circRNAs in RNA sequencing data previously generated from astrocytes microdissected from the posterior cingulate (PC) of Alzheimer's disease (AD) patients (N = 10) and healthy elderly controls (N = 10) using four circRNA prediction algorithms - CIRI, CIRCexplorer, find_circ and KNIFE.Entities:
Keywords: Aging; Astrocytes; Circular RNAs; Posterior cingulate; Regulatory network
Mesh:
Substances:
Year: 2018 PMID: 29739336 PMCID: PMC5941680 DOI: 10.1186/s12864-018-4670-5
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Fig. 1Summary of circRNA prediction results. a Number of unique and common circRNAs in AD and ND PC. b Read count distribution of all detected circRNAs. c Intersection of circRNAs called by the four tools; the red bar indicates the number of circRNAs called by all four tools d Size distribution of all detected circRNAs. e Violin plots indicating the number of circRNAs predicted by each tool across PC samples along with the probability density. f Number of circRNAs predicted by each tool across PC samples, condition-wise. AD, Alzheimer’s disease; ND, no disease; circRNA, circular RNA; PC, posterior cingulate; bp, base pairs
Fig. 2circRNA-miRNA network. a circRNA-miRNA interactions with 100 or more predicted binding sites. Red circular nodes: circRNAs, green triangular nodes: miRNAs. b miRNA network of CDR1as. The edge thickness in a and b is weighted by the number of binding sites predicted for the circRNA-miRNA interaction. miRNA, microRNA
Fig. 3High stringency circRNA-miRNA-mRNA regulatory network. Network of circRNA-miRNA-mRNA regulation for those circRNA-miRNA interactions predicted by both RNAHybrid and miRanda, with a miRanda match score > = 180 and mRNA targets with differential expression (uncorrected P < 0.05) and log2(fold change) ≥ 2 or ≤ − 2. Red circular nodes: circRNAs, green triangular nodes: miRNAs, blue square nodes: genes. mRNA, messenger RNA
circRNA-miRNA-mRNA network elements for those circRNA-miRNA interactions predicted by both miRanda and RNAHybrid, with a miRanda match score > = 180 and mRNA targets that are differentially expressed (uncorrected P < 0.05) with log2(fold change) >= 2 or =< − 2 (high stringency network)
| Circular RNA | microRNA target | Number of binding sites predicted | Target genes (differentially expressed) |
|---|---|---|---|
| X:47,431,299–48,327,824 | hsa-miR-139-5p | 6 |
|
| 8:144,989,320–145,838,888 | hsa-miR-320a | 2 |
|
| 8:144,989,320–145,838,888 | hsa-miR-320b | 2 |
|
| X:47,431,299–48,327,824 | hsa-miR-449a | 1 |
|
| 8:144,989,320–145,838,888 | hsa-miR-125a-3p | 1 |
|
| X:47,431,299–48,327,824 | hsa-miR-125a-5p | 1 |
|
| 8:144,989,320–145,838,888 | hsa-miR-125a-5p | 1 |
|
| X:47,431,299–48,327,824 | hsa-miR-324-5p | 1 |
|
| 14:23,815,526–24,037,279 | hsa-miR-142-3p | 1 |
|
| 4:88,394,487–89,061,166 | hsa-miR-133b | 1 |
|
| 4:88,394,487–89,061,166 | hsa-miR-448 | 1 |
|
| 4:88,394,487–89,061,166 | hsa-miR-339-5p | 1 |
|
Top 25 pathways with FDR corrected P < 0.01 from Metacore GeneGO pathway analysis. Remaining pathways with corrected P < 0.01 summarized in Additional file 8: Table S5. *Ratio: Number of genes in input list found in the pathway/Total number of genes in the pathway
| Pathway | Corrected | *Ratio | Encoded proteins/protein complexes in input list |
|---|---|---|---|
| Aberrant B-Raf signaling in melanoma progression | 7.456E-07 | 10/55 | BAD, NOTCH1 (NICD), AKT1, Nicastrin, CBP, mTOR, ERK1/2, ERK2 (MAPK1), Mcl-1, AKT(PKB) |
| Signal transduction_PTMs in BAFF-induced signaling | 3.454E-06 | 9/51 | BAD, ERK1 (MAPK3), AKT1, MEKK1(MAP3K1), FKHR, mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
| Immune response_IL-15 signaling | 9.177E-06 | 9/61 | ERK1 (MAPK3), AKT1, MEKK1(MAP3K1), mTOR, ERK1/2, UFO, ERK2 (MAPK1), Mcl-1, AKT(PKB) |
| Development_Ligand-independent activation of ESR1 and ESR2 | 9.177E-06 | 8/44 | EGFR, ERK1 (MAPK3), PKA-cat (cAMP-dependent), G-protein alpha-s, CBP, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
| Translation_Regulation of EIF4F activity | 3.883E-05 | 8/54 | EGFR, MEKK1(MAP3K1), eIF4B, PP2A catalytic, eIF4A, mTOR, ERK1/2, AKT(PKB) |
| Aberrant production of IL-2 and IL-17 in SLE T cells | 5.718E-05 | 8/58 | PP2A cat (alpha), NOTCH1 (NICD), PKA-cat (cAMP-dependent), CBP, mTOR, ERK1/2, AKT(PKB), NOTCH1 precursor |
| IGF family signaling in colorectal cancer | 6.001E-05 | 8/60 | ERK1 (MAPK3), IBP, MNK2(GPRK7), mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB), Clusterin |
| Apoptosis and survival_BAD phosphorylation | 6.001E-05 | 7/42 | BAD, EGFR, PKA-cat (cAMP-dependent), PP2A catalytic, G-protein alpha-s, ERK1/2, AKT(PKB) |
| Influence of smoking on activation of EGFR signaling in lung cancer cells | 7.422E-05 | 7/44 | EGFR, ERK1 (MAPK3), PKA-cat (cAMP-dependent), MEKK1(MAP3K1), G-protein alpha-s, ERK1/2, ERK2 (MAPK1) |
| Immune response_IL-6 signaling pathway via JAK/STAT | 1.810E-04 | 8/72 | MEKK1(MAP3K1), FKHR, CCL2, CBP, mTOR, Mcl-1, AKT(PKB), gp130 |
| Signal transduction_Erk Interactions: Inhibition of Erk | 1.810E-04 | 6/34 | MKP-3, PKA-cat (cAMP-dependent), PP2A catalytic, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
| Oxidative stress_ROS-mediated activation of MAPK via inhibition of phosphatases | 1.810E-04 | 6/34 | EGFR, MKP-3, SOD2, PP2A catalytic, ERK1/2, SOD1 |
| Apoptosis and survival_NGF/ TrkA PI3K-mediated signaling | 2.255E-04 | 8/77 | BAD, N-WASP, AKT1, FKHR, ILK, mTOR, ERK1/2, AKT(PKB) |
| PGE2 pathways in cancer | 2.255E-04 | 7/55 | EGFR, ERK1 (MAPK3), TGF-alpha, PKA-cat (cAMP-dependent), G-protein alpha-s, ERK2 (MAPK1), AKT(PKB) |
| Immune response_Oncostatin M signaling via MAPK | 2.275E-04 | 6/37 | ERK1 (MAPK3), MEKK1(MAP3K1), CCL2, ERK1/2, ERK2 (MAPK1), gp130 |
| Development_Beta-adrenergic receptors transactivation of EGFR | 2.275E-04 | 6/37 | EGFR, ERK1 (MAPK3), PP2A catalytic, mTOR, ERK1/2, ERK2 (MAPK1) |
| Development_Regulation of lung epithelial progenitor cell differentiation | 3.976E-04 | 6/41 | FOXP2, SMAD4, Frizzled, NOTCH1 receptor, FOXP1, O-fucose |
| Regulation of Tissue factor signaling in cancer | 4.726E-04 | 6/43 | EGFR, ERK1 (MAPK3), mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |
| Development_Adenosine A2A receptor signaling | 4.726E-04 | 6/43 | BAD, PKA-cat (cAMP-dependent), MEKK1(MAP3K1), G-protein alpha-s, ERK1/2, AKT(PKB) |
| Development_VEGF signaling via VEGFR2 - generic cascades | 5.478E-04 | 8/93 | ERK1 (MAPK3), MEKK1(MAP3K1), CCL2, Vinculin, ERK1/2, ERK2 (MAPK1), AKT(PKB), Fyn |
| Signal transduction_mTORC2 downstream signaling | 5.478E-04 | 7/68 | BAD, AKT1, PKA-cat (cAMP-dependent), FKHR, mTOR, Mcl-1, AKT(PKB) |
| Transcription_Hypoxia- and receptor-mediated HIF-1 activation | 5.478E-04 | 6/46 | EGFR, FKHR, MNK2(GPRK7), CBP, ERK1/2, AKT(PKB) |
| Transcription_Androgen Receptor nuclear signaling | 5.478E-04 | 6/46 | EGFR, AKT1, PKA-cat (cAMP-dependent), Frizzled, ERK2 (MAPK1), AKT(PKB) |
| Signal transduction_PTEN pathway | 5.478E-04 | 6/46 | BAD, EGFR, ILK, mTOR, ERK1/2, AKT(PKB) |
| Immune response_IL-4 signaling pathway | 5.478E-04 | 8/94 | BAD, PDE3A, MEKK1(MAP3K1), FKHR, mTOR, ERK1/2, ERK2 (MAPK1), AKT(PKB) |